Fig. 4: The four-lncRNA classifier identified suitable candidates for PFS and OS in different patient subgroups. | Cell Death Discovery

Fig. 4: The four-lncRNA classifier identified suitable candidates for PFS and OS in different patient subgroups.

From: A long noncoding RNA-based serum signature predicts ado-trastuzumab emtansine (T-DM1) treatment benefit in HER2+ metastatic breast cancer patients: a multicenter cohort study

Fig. 4

A Forest plot depicting multivariate Cox regression model analysis of clinical features and survival status in the entire cohort (training, internal, and independent validation cohorts). p values were calculated via the two-sided log-rank test. B Forest plot for the performance of the Cox model in predicting the risk score in terms of PFS stratified by clinicopathological features. p values were calculated via the two-sided log-rank test. HRs and 95% CIs are given and are visually represented by circles and error bars. ECOG Eastern Cooperative Oncology Cohort, ER estrogen receptor, PR progesterone receptor, HR hazard ratio, CI 95% confidence interval.

Back to article page